News - Arzerra

Filter

Current filters:

Arzerra

Popular Filters

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Positive developments for GSK's Tafinlar/Mekinist and Arzerra

16-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) has announced positive news relating to three of its drugs,…

ArzerraBiotechnologyGenmabGlaxoSmithKlineMekinistNorth AmericaOncologyPharmaceuticalRegulationTafinlar

US Court denies re-hearing of Arzerra patent case

16-07-2013

Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Arzerra and ospemifene NDAs submitted in Japan

02-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Danish company Genmab A/S (OMX: GEN) have submitted a…

ArzerraAsia-PacificGenmabGlaxoSmithKlineOncologyospemifenePharmaceuticalQuatRx PharmaRegulationShionogiWomen's Health

GSK settles with Genentech over ofatumumab patents

28-03-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has agreed a settlement with Genentech, a unit of Roche (ROG:…

ArzerraBiotechnologyGenentechGenmabGlaxoSmithKlineLegalOfatumumab InjectionOncologyPatentsPharmaceuticalRoche

US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute

18-11-2011

A US District Court has entered final judgment in favor of UK pharma giant GlaxoSmithKline (LSE: GSK)…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceuticalRoche

Non-Hodgkins lymphoma drug market set to more than double by 2019

05-05-2011

Driven by the launches of premium-priced therapies, the non-Hodgkin’s lymphoma drug market will…

ArzerraGlaxoSmithKlineMarkets & MarketingOncologyPharmaceuticalRituxanrituximabRoche

Back to top